Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1) [Etude Phase I/II d'immunotherapie Par proteine recWT1-A10+AS01B apres Greffe allogenique de Cellules Souches]

Trial Profile

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1) [Etude Phase I/II d'immunotherapie Par proteine recWT1-A10+AS01B apres Greffe allogenique de Cellules Souches]

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acute myeloid leukaemia vaccine (Primary) ; AS01B
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms ALLO-WT1
  • Most Recent Events

    • 19 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2013 New source identified and integrated: European Clinical Trials Database record.
    • 10 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top